ASX:MSB
Mesoblast Ltd
Investment Summary
The fund managers believe that while Mesoblast Limited shares rose 75% in December, the company is not held by the fund. In their opinion, the recent FDA approval for Ryoncil, a cell-based therapy for SR-aGvHD, is a significant milestone as it marks the first cell-based drug approved by the FDA. However, they express concerns regarding the management skillset necessary for commercialization, which may not align with MSB's current leadership. Despite this, the fund managers acknowledge that the FDA approval has increased the business's value, potentially making it more attractive for acquisition or investment by others.
Commentary From The Managers
Blackwattle Investment Partners
31 Dec 2024
$3.10
- Blackwattle Investment Partners observed a 75% rise in Mesoblast Limited shares in December.
- Despite this increase, Blackwattle Investment Partners did not hold shares in the company.
- MSB received FDA approval for Ryoncil, a cell-based therapy for treating SR-aGvHD.
- This marks the first FDA approval for a cell-based drug.
- Mesoblast’s approval process was lengthy and complex.
- As Ryoncil approaches the commercialization phase, Blackwattle Investment Partners believes different management skills may be needed.
- There is uncertainty regarding whether the current MSB management possesses these skills.
- FDA approval has enhanced the business's value, suggesting it may be more valuable in different hands.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.